CD274 and neoplasm: PD-1 is activated by ligand PD-L1, which is expressed by tumor cells and infiltrating immune cells, and inhibition of this interaction between the PD-1 receptor and ligand can enhance anti-tumor immunity, resulting in durable tumor control (4).